Our cutting-edge RNA sequencing technology and state-of-the-art artificial intelligence platform deliver personalized, preventative oral health solutions to dental professionals, empowering you to optimize patient outcomes.
An unhealthy oral microbiome can lead to chronic conditions
The oral microbiome has been the focus of intense research in recent years. As the entry point to your entire body, it is no surprise that in addition to mouth diseases, the oral microbiome has been implicated in many systemic diseases.
Problems with oral health caused by underlying, suboptimal microbial activities—such as cavities, gum disease, and tooth loss—can and do affect overall health. In recent years, science has linked the oral microbiome to many chronic diseases and health issues.
Microbial and human gene expression are redefining how biological activities are viewed in relation to human health. Viome's metatranscriptomic technology is the only clinically validated metatranscriptomic technology in the world.
RNA plays a fundamental role in human biology referring the instructions stored in DNA to make the proteins required in every living cell. Our approach is to use RNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease.
Oral Pro Health Scores
Unlike other tests that focus on composition, our RNA sequencing technology enables us to measure the molecular activity of the oral microbiome and human cells in your patient’s mouth and identify early biomarkers of periodontitis disease, caries, gum inflammation, and other risks of oral and systemic diseases. With these scores, you can monitor the underlying signals of poor oral health and disease over time, and take action with a personalized treatment plan that addresses your patient’s unique needs.
Oral & Throat
Our CancerDetect®- Oral & Throat test was developed over multiple years by Viome Life Sciences, Inc, based on clinical studies for diagnostic development and validation. This test is a non-invasive, at-home test that detects a molecular signature associated with Oral and/or Throat cancers with high accuracy.
Viome’s commercially available CancerDetect Oral and Throat cancer test is a laboratory-developed test (LDT). This test was clinically validated with an independent cohort, with a specificity of at least 95% and a sensitivity of at least 90% for both Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal Squamous Cell Carcinoma (OPSCC). This surpasses the current standard of care - the visual and tactile exam.
In addition to head and neck cancers, Viome has an extensive ongoing clinical study pipeline in gastrointestinal cancers including colorectal cancer, pancreatic, ovarian, cervical, and biliary cancers. We currently have cancer research trials that use saliva, blood, stool, and tumor biopsies to understand the onset and progression of cancer. By identifying the biomarkers that lead to the development of cancers, Viome can optimize early detection and identify the right therapeutic targets.
Work With Us
We founded Viome Life Sciences with one goal in mind: to tackle the epidemic of chronic diseases, cancer, and aging and empower people with the information they need to live a disease-free life.